Skip to main content
Premium Trial:

Request an Annual Quote

BioMérieux EpiSeq

BioMérieux has launched EpiSeq, a next-generation sequencing service for epidemiological monitoring and control of healthcare-associated infections.

EpiSeq is the first result of a collaboration signed between BioMérieux and Illumina in November 2014 to couple the companies' expertise in microbiology and NGS for microbiology sequencing. Customers of the new service will be able to send bacterial isolates to a service laboratory designated by BioMérieux and equipped with an Illumina MiSeq instrument. The genomic data is stored in a secure cloud platform and analyzed using a database and software developed by BioMérieux. Results showing the genomic profile of the infectious agent and the genetic variations identified by sequencing will be sent by BioMérieux to healthcare professionals in a customized report.

BioMérieux is launching the service first in Europe followed by North America and Asia. The menu will initially consist of Staphylococcus aureus and will subsequently be expanded to include other bacterial species most commonly responsible for HAIs.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more